MIRA Pharmaceuticals, Inc. (MIRA) has shared an announcement.
Mira Pharmaceuticals, Inc. has undergone a significant board reshuffle to enhance scientific expertise ahead of a future Investigational New Drug Application. After voluntary resignations, new members with strong backgrounds in radiology and marketing joined the board, with the CEO now also serving as Chairman. Additionally, the company has secured the expertise of Dr. Itzchak Angel as Chief Scientific Advisor, leveraging his 30 years of pharmaceutical industry experience to guide the company’s strategic drug development and regulatory affairs.
For an in-depth examination of MIRA stock, go to TipRanks’ Stock Analysis page.
